| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
354.94(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Schaffer Derace L |
Director |
– • – |
2017-11-27 |
4 |
B |
$2.00 |
$20,060 |
D/D |
10,042 |
261,843 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-11-24 |
4 |
B |
$2.02 |
$13,162 |
D/D |
6,505 |
251,801 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-11-22 |
4 |
B |
$2.10 |
$11,061 |
D/D |
5,261 |
245,296 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-11-21 |
4 |
B |
$2.06 |
$14,905 |
D/D |
7,236 |
240,035 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-11-20 |
4 |
B |
$2.07 |
$9,958 |
D/D |
4,800 |
232,799 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-11-17 |
4 |
B |
$2.12 |
$13,352 |
D/D |
6,295 |
227,999 |
2.39 |
- |
|
| Novartis Ag |
10% Owner |
– – • |
2017-11-14 |
4 |
A |
$0.00 |
$0 |
I/I |
182,262 |
2,049,563 |
|
- |
|
| Truffle Capital S.a.s. |
10% Owner |
– – • |
2017-11-14 |
4 |
A |
$0.00 |
$0 |
I/I |
40,099 |
22,418 |
|
- |
|
| Redmont Vaxn Capital Holdings, Llc |
Director |
– • – |
2017-10-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,278,471) |
0 |
|
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-08-25 |
4 |
B |
$2.25 |
$112,390 |
D/D |
50,000 |
221,704 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-08-24 |
4 |
B |
$2.24 |
$38,892 |
D/D |
17,326 |
171,704 |
2.39 |
- |
|
| Drutz David |
Director |
– • – |
2017-08-23 |
4 |
B |
$2.27 |
$11,340 |
D/D |
5,000 |
30,777 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-08-23 |
4 |
B |
$2.22 |
$96,350 |
D/D |
43,352 |
154,378 |
2.39 |
- |
|
| Drutz David |
Director |
– • – |
2017-08-22 |
4 |
B |
$2.15 |
$10,758 |
D/D |
5,000 |
25,777 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-08-22 |
4 |
B |
$2.10 |
$12,519 |
D/D |
5,958 |
111,026 |
2.39 |
- |
|
| Schaffer Derace L |
Director |
– • – |
2017-08-21 |
4 |
B |
$2.02 |
$1,395 |
D/D |
690 |
105,068 |
2.31 |
- |
|
| Enright William |
President and CEO |
• • – |
2017-08-16 |
4 |
OE |
$0.08 |
$13,070 |
D/D |
163,377 |
181,164 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2017-06-06 |
4 |
B |
$4.42 |
$1,985 |
I/I |
449 |
449 |
1.91 |
- |
|
| Gill John |
Director |
– • – |
2017-06-02 |
4 |
B |
$4.34 |
$4,344 |
D/D |
1,000 |
83,224 |
2.31 |
- |
|
| Truffle Capital S.a.s. |
10% Owner |
– – • |
2017-05-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,560,393 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2017-05-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,867,301 |
|
- |
|
| Paradigm Venture Partners, L.p. |
10% Owner |
– – • |
2017-05-04 |
4 |
A |
$0.00 |
$0 |
I/I |
1,319,711 |
4,455 |
|
- |
|
| Schafer Klaus |
Director |
– • – |
2017-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
5,998 |
5,998 |
|
- |
|
| Enright William |
See Remarks |
• • – |
2017-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
17,787 |
17,787 |
|
- |
|
| Drutz David |
Director |
– • – |
2017-05-04 |
4 |
A |
$0.00 |
$0 |
D/D |
20,777 |
20,777 |
|
- |
|
260 Records found
|
|
Page 9 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.50 (6.48%) 
